Table 2.

Driver and nondriver genes and associated mutations in lung and GI malignancies

Tissue genes (exact mutationsBlood genes (exact mutations)
(n = 51)(n = 53)
Pt #Age (years)Gender (M/F)DiagnosisBiopsy siteNo. of metastatic lesionsTreatmentDriver mutations (n = 33)Non-driver mutations (n = 18)Driver mutations (n = 39)Non-driver mutations (n = 14)
161MAdenocarcinoma of lungPleura1Carboplatin+PemetrexedTP53 (G266E)CCNE1 (N64D)
JAK3 (P843Q)
278FAdenocarcinoma of lungLung2CrizotinibTP53 (C673)EML4/ALKNTRK1(R347C)
343MCholangiocarcinomaCommon bile duct>3FOLFOX on progressionFGFR3 (Amplification)ATM (R1575H)KRAS (A146T)APC (S2028R)
TP53 (R280)GATA3 (A109S)KRAS (Amplification)FGFR3 (S408F)
SMAD4 (357P)
478MAdenocarcinoma of lungLiver>3ErlotinibEGFR (G719A)ATM (L271)EGFR (G719A)
EGFR (S768I)EGFR (S768I)
553MAdenocarcinoma of lungBrain2Carboplatin+PemetrexedKRAS (G12C)RB1 (I274T)
TP53 (G105V)
666MPancreatic ductal adenocarcinomaLiver>3Gemcitabine+Neb-paclitaxel+ indoximod (on clinical trials)KRAS (G12V)CTNNB1 (R542H)ATM (R3008C)
SMAD4 (R361C)TP53 (S241Y)
CDKN2A (L78fs)TP53 (G244D)
TP53 (L252dup)TP53 (N235K)
736MColorectal adenocarcinomaRectum>3FOLFOX + BevacizumabAPC (A1492Fs)DDR2 (L324P)NOTCH1 (E159K)
FBXW7 (R479P)IDH1 (R388H)
KRAS (G12)TP53 (T18Fs)
SMAD4 (Y353fs)
864FColorectal adenocarcinomaLiver>3FOLFOXTP53 (G245S)APC (Q1367X)TP53 (M237I)
ERBB2 (S28N)TP53 (T256P)
FGFR3 (P739A)
GATA3 (K254N)
962MColorectal adenocarcinomaAbdomen NOS3FOLFOX + BevacizumabKRAS (G12)
TP53 (R175H)
APC (R213X)
APC (P1440Fs)
1045MColorectal adenocarcinomaRectum1FOLFOX + BevacizumabKRAS (G12D)FGFR1 (T141R)KRAS (G12D)
TP53 (R248W)MYC (Amplification)
TP53 (R248W)
1167MSmall-cell lung carcinomaLiver>3Carboplatin+etoposide+ Rovalpituzumab tesirine (Trial on progression)GNAS (V137M)NF1 (R816*)ALK (A1200V)
RB1 (R66Fs)PIK3CA (Amplification)
TP53 (G187Fs)
1270FAdenocarcinoma of lungRight axillary lymph node2Carboplatin+Pemetrexed. Nivolumab on progressionCDK6 (Amplification)
FGFR1 (Amplification)
1379FAdenocarcinoma of lungPleural fluid1NivolumabKRAS (G12C)MET (S22R)
RET (R693C)
1467MColorectal adenocarcinomaLiver2FOLFOXNo mutation detected
1567FAdenocarcinoma of lungAdrenal gland>3AfatinibEGFR (Exon 19 Insertion)BRCA2 (R2842H)
EGFR (Amplification)
CDK4 (Amplification)
EGFR (Exon 19 Insertion)
1667FAdenocarcinoma of lungBrain1Carboplatin+PemetrexedNo mutation detected
1782FAdenocarcinoma of lungLung3GefitinibEGFR (L858R)KIT (T670I)PDGFRA (1090Q)
PIK3CA (e542k)
1874MGastroesophageal junction carcinomaLiver2HospiceERBB2 (Amplification)ERBB2 (Amplification)
ERBB2 (D769Y)
MET (Amplification)
TP53 (I195T)
MYC (Amplification)
TP53 (S127F)
1965MGastric adenocarcinomaPeritoneum1FOLFIRINOXNo mutation detected
2073MEsophageal squamous cell carcinomaEsophagus3Carboplatin+PaclitaxelNo mutation detectedCCND1 (Amplification)
2168MAdenocarcinoma of lungLiver2Lost follow upTP53 (R248L)TP53 (R248W)
TP53 (R248Q)
2262MSmall-cell lung carcinomaMediastinal Lymph node>3Carboplatin+EtoposideNo mutation detectedPIK3CA (Amplification)ERBB2 (Q568*)
2372MSmall-cell lung carcinomaMediastinal Lymph node>3Carboplatin+EtoposideNo mutation detectedTP53 (Y220S)
2463MIntrahepatic cholangiocarcinomaLiver>3Cisplatin + GemcitabineIDH1 (R132C)IDH1 (R132C)FGFR2 (P700L)
BRAF (D594N)
NRAS (G12S)
2574MSmall-cell lung carcinomaChest wall mass>3Carboplatin+EtoposideNo mutation detectedTP53 (R181P)
2679MHepatocellular carcinomaLiver1HospiceNo mutation detectedTP53 (R273H)RET (D631N)
2762FColorectal adenocarcinomaVaginal apex>3FOLFOXKRAS (Q61H)KRAS (Q61H)HRAS (R161C)
CCND2 (Amplification)TP53 (R267Q)
2877FHepatocellular carcinomaPubic bone>3Sorafinib followed by NivolumabNo mutation detected
  • NOTE: Amino acid change and site are shown in parenthesis.